Consensus (31c). Raises FY23 revenue view to $747M-$753M from $730M-$750M, consensus $739.52M. Sees FY23 adjusted operating expenses $548M-$553M. The company said, “Myriad Genetics’ fiscal year 2023 non-GAAP guidance begins with the comparable GAAP financial measure and excludes the estimated impact of stock-based compensation expense of approximately $40.0 million, non-cash amortization associated with acquisitions of approximately $48.0 million and special items such as costs related to transformation initiatives of approximately $24.0 million, legal settlement costs of approximately $114.0 million, and tax adjustments of approximately $8.0 million.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
- Myriad Genetics appoints Raha as Chief Operating Officer
- Myriad Genetics Appoints Sam Raha as Chief Operating Officer
- Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
- Is MYGN a Buy, Before Earnings?